Dr. Laurie H. Glimcher is the president and chief executive officer of the Dana-Farber Cancer Institute, and also serves on the National Cancer Moonshot Blue Ribbon Panel.
Dr. Glimcher first achieved renown for her discoveries involving the differentiation of T cells, especially CD4+ T cells, which earned her the 2012 William B. Coley Award for Distinguished Research in Basic Immunology, the L'Oréal-UNESCO Award for Women in Science, and election to the National Academy of Sciences, among other honors.
Dr. Glimcher has been a member of CRI’s Scientific Advisory Council since 2006.
Immune-based approaches have succeeded in other lethal cancers, such as melanoma, and it may be very beneficial as well in ovarian cancer.
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.